PMV announces 31 August rezatapopt ovarian update for PYNNACLE

Prognyx view: PMV Pharmaceuticals’ 31 August 2026 update keeps rezatapopt in the mutant-p53 diligence file, but the dossier supports PMV’s prior May ORR and NDA-plan story rather than the actual 31 August efficacy or safety cut.^[1][3]

What happened

On 31 August 2026, PMV announced updated interim rezatapopt monotherapy ovarian cancer data from PYNNACLE, the TP53 Y220C advanced-solid-tumor study that includes the ovarian cancer dataset PMV is positioning for a planned NDA.^[1][2][3] ClinicalTrials.gov identifies PYNNACLE as NCT04585750, a Phase 1/Phase 2 study of rezatapopt in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation, including a Phase 1b combination component with pembrolizumab.^[2] The registry context dated 10 August 2026 lists PYNNACLE as recruiting, with no posted results, planned enrollment of 300, a start date of 29 October 2020, and a primary completion date of 15 August 2026.^[2]

PMV had already framed the Phase 2 monotherapy portion as a multicenter, single-arm, registrational Phase 2 study assessing rezatapopt 2000 mg once daily in patients with TP53 Y220C advanced solid tumors.^[3] The earlier pivotal design called for 114 patients across five cohorts at about 60 sites, with overall response rate by blinded independent central review as the primary endpoint.^[4] PMV said on 12 May 2026 that it anticipated submitting an NDA for rezatapopt in platinum-resistant or platinum-refractory ovarian cancer patients with a TP53 Y220C mutation in the first quarter of 2027.^[3]

The efficacy bar visible in the dossier comes from PMV’s 12 May 2026 SEC 8-K exhibit, not the 31 August update, and it remains company-reported and investigator-assessed rather than ClinicalTrials.gov-posted results.^[2][3] In that filing, PMV reported 2026 Society of Gynecologic Oncology data showing investigator-assessed ORR of 44%, or 32 of 72 patients, including one confirmed complete response and 31 confirmed partial responses, in platinum-resistant or platinum-refractory ovarian cancer patients with a TP53 Y220C mutation.^[3] PMV also reported median time to response of 1.3 months and median duration of response of 8.2 months in those updated Phase 2 PYNNACLE ovarian cancer results.^[3] After the 29 March 2026 data cutoff, PMV said two additional patients achieved unconfirmed partial responses, bringing ORR to 46%, or 34 of 74 patients.^[3]

Why it matters

In the provided 10 August snapshot—not a post-announcement registry check—the 31 August announcement falls after the listed 15 August 2026 primary completion date and before PMV’s stated first-quarter 2027 NDA-submission plan.^[1][2][3] For an R&D or BD team, the question is no longer whether mutant-p53 reactivation has a disclosed ovarian signal; PMV has already disclosed investigator-assessed responses, duration, and a company-stated Q1 2027 NDA submission plan in a defined TP53 Y220C platinum-resistant or platinum-refractory ovarian population.^[3] The research question is whether the 31 August update tightens the package enough to support a single-arm registrational argument built around central-review ORR, durability, safety, and molecular selection.^[1][3][4]

Rezatapopt is mutation-specific in the dossier.^[3] PMV describes rezatapopt, also named PC14586, as a small-molecule p53 reactivator designed to selectively bind the pocket in the p53 Y220C mutant protein and restore wild-type tumor-suppressor function.^[3] The dossier contains two 2026 DOI-title records on targetable p53, but no article text.^[8][9]

If a future central-review ORR is directionally consistent with the investigator-assessed 44% ORR, comparator diligence would likely focus on mutation specificity, denominator, duration maturity, and filing readiness.^[3][4][6][7] The ovarian efficacy data in the dossier are SEC-disclosed company data, investigator-assessed, and not ClinicalTrials.gov-posted results.^[2][3] That distinction matters because the pivotal claim ultimately rests on whether the blinded independent central review endpoint in the 114-patient five-cohort design supports the same story as investigator-assessed interim data.^[3][4]

Relevant comparators in the dossier — by name

Prognyx classifies Jacobio Pharmaceuticals as the closest named comparator in the dossier because it sponsors NCT06386146, a recruiting Phase 1/Phase 2 trial of JAB-30355 in patients with advanced solid tumors harboring TP53 Y220C mutation.^[6] Jacobio is target-adjacent by TP53 Y220C registry similarity, although the dossier states only what is being tested and does not report efficacy.^[6]

Clasp Therapeutics is relevant only as a broader p53-mutant biology comparator; the dossier does not establish direct Y220C or ovarian competition.^[7] Clasp sponsors NCT06778863, a recruiting Phase 1 trial of CLSP-1025 in adults with solid tumors that harbor the p53 R175H mutation.^[7] The dossier supports Clasp’s presence in p53-mutant solid tumors, but it does not establish direct exposure to rezatapopt’s Y220C ovarian filing dynamics.^[3][7]

Other trial records in the dossier are less directly relevant to rezatapopt’s immediate competitive set.^{[10][11][12][13][14]} The other cited records include non-p53 programs, including mTORC1/2 or AKT, HER2, EGFR, and a separate RxFINE-Low breast-cancer record; the dossier does not establish any as p53-reactivation competitors.^{[10][11][12][13][14]} Treating those programs as direct threats would overstate the registry evidence provided here.^{[10][11][12][13][14]}

Evidence limits

Prognyx could not confirm the full numeric efficacy or safety details from PMV’s 31 August 2026 updated interim ovarian cancer release from the supplied dossier excerpt; the dossier establishes that the announcement occurred, but it does not provide the new ORR, duration, safety, cutoff date, central-review result, or response-evaluable denominator from that release.^[1] Prognyx could not confirm a 31 August 2026 SEC 8-K, an FDA approval record, an NDA filing or acceptance, an FDA label, or a post-10 August 2026 ClinicalTrials.gov update from the supplied dossier.^[1][2][3]

What to watch next

The immediate data gap is the exact 31 August 2026 table, because the dossier’s last complete efficacy numbers remain the 44% investigator-assessed ORR in 32 of 72 patients, median time to response of 1.3 months, median duration of response of 8.2 months, and 46% ORR including two unconfirmed partial responses after the 29 March 2026 cutoff.^[1][3] When the full 31 August table is obtained, check whether it adds central-review ORR, response-evaluable denominator, duration maturity, cutoff date, and tolerability at 2000 mg once daily.^[1][3][4]

The next dated company marker is PMV’s stated first-quarter 2027 NDA submission plan for rezatapopt in TP53 Y220C platinum-resistant or platinum-refractory ovarian cancer.^[3] The dossier provides no FDA filing, acceptance, action-date trigger, or review designation; no FDA decision window should be inferred.^[3]

PYNNACLE’s registry record after the 15 August 2026 primary completion date listed in the 10 August 2026 context remains important.^[2] A status change, results posting, enrollment update, or endpoint update would clarify whether the public registry has caught up to PMV’s press and SEC disclosures.^[1][2][3][4]

PMV’s next combination move also matters.^[4][5] PMV said dose-limiting toxicities in the Phase 1b pembrolizumab combination arm led to rezatapopt 500 mg once daily plus pembrolizumab 200 mg every three weeks being established as the maximum tolerated dose, and PMV later discontinued enrollment in that arm because patients did not experience clinically meaningful benefit at that dose.^[4][5] That leaves the near-term rezatapopt story concentrated on monotherapy and on mutation-selected development outside the discontinued pembrolizumab combination arm.^[3][4][5]

The now-what

First, p53 competitors should audit their own mutation-specific positioning against PMV’s TP53 Y220C ovarian package: molecular gate, response endpoint, blinded independent central review plan, and registrational use case.^[3][4][6][7] Programs without a defined molecular gate, response endpoint, central-review plan, and registrational use case remain less comparable to PMV’s stated ovarian NDA plan.^[3][4]

Second, BD teams should separate platform value from filing value by evidence gate.^[3][4] The gates are denominator, blinded independent central review ORR, duration-of-response maturity, safety at rezatapopt 2000 mg once daily, and whether the ovarian cohort alone can support PMV’s planned first-quarter 2027 NDA submission.^[1][3][4]

Third, any partner diligence should focus on the missing 31 August details before underwriting the read-through.^[1] The sharper question is whether the newer update confirms the May company-reported, investigator-assessed story in a way that aligns with the central-review primary endpoint PMV previously described.^[1][3][4]

Working view: do not upgrade competitive threat until the 31 August table shows response-evaluable denominator, central-review ORR, duration-of-response maturity, cutoff date, and tolerability at 2000 mg once daily.^{[1][3][4][6][7]}